Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

被引：17

作者：

Heudel, P. ^{[1
]}

Chabaud, S. ^{[1
]}

Perol, D. ^{[1
]}

Flechon, A. ^{[1
]}

Fayette, J. ^{[1
]}

Combemale, P. ^{[1
]}

Tredan, O. ^{[1
,2
]}

Desseigne, F. ^{[1
]}

de la Fouchardiere, C. ^{[1
]}

Boyle, H. ^{[1
]}

Perol, M. ^{[1
]}

Bachelot, T. ^{[1
,2
]}

Cassier, P. ^{[1
]}

Avrillon, V ^{[1
]}

Terret, C. ^{[1
]}

Michallet, A-S ^{[1
]}

Neidhardt-Berard, E-M ^{[1
]}

Nicolas-Virelizier, E. ^{[1
]}

Dufresne, A. ^{[1
,2
]}

Belhabri, A. ^{[1
]}

Brahmi, M. ^{[1
,2
]}

Lebras, L. ^{[1
]}

Nicolini, F. ^{[1
,2
]}

Sarabi, M. ^{[1
,2
]}

Rey, P. ^{[1
]}

Bonneville-Levard, A. ^{[1
]}

Rochefort, P. ^{[1
]}

Provensal, A-M ^{[1
]}

Eberst, L. ^{[1
]}

Assaad, S. ^{[1
]}

Swalduz, A. ^{[1
]}

Saintigny, P. ^{[1
,2
]}

Toussaint, P. ^{[1
]}

Guillermin, Y. ^{[1
]}

Castets, M. ^{[1
,2
]}

Coutzac, C. ^{[1
,2
]}

Meeus, P. ^{[1
]}

Dupre, A. ^{[1
]}

Durand, T. ^{[1
]}

Crochet, H. ^{[1
]}

Fervers, B. ^{[1
]}

Gomez, F. ^{[1
]}

Rivoire, M. ^{[1
,3
]}

Gregoire, V ^{[1
]}

Claude, L. ^{[1
]}

Chassagne-Clement, C. ^{[1
]}

Pilleul, F. ^{[1
,3
]}

Mognetti, T. ^{[1
]}

Russias, B. ^{[1
]}

Soubirou, J-L ^{[1
]}

机构：

[1] Ctr Leon Berard, Lyon, France

[2] Canc Res Ctr Lyon CRCL, Lyon, France

[3] Univ Claude Bernard, Lyon, France

[4] Unicancer, Paris, France

来源：

ESMO OPEN | 2021年 / 6卷 / 01期

关键词：

immunotherapy; immune checkpoints; second primary cancer; second malignant neoplasia;

D O I：

10.1016/j.esmoop.2020.100044

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Second primary cancers (SPCs) are diagnosed in over 5% of patients after a first primary cancer (FPC). We explore here the impact of immune checkpoint inhibitors (ICIs) given for an FPC on the risk of SPC in different age groups, cancer types and treatments. Patients and methods: The files of the 46 829 patients diagnosed with an FPC in the Centre Leon Berard from 2013 to 2018 were analyzed. Structured data were extracted and electronic patient records were screened using a natural language processing tool, with validation using manual screening of 2818 files of patients. Univariate and multivariate analyses of the incidence of SPC according to patient characteristics and treatment were conducted. Results: Among the 46 829 patients, 1830 (3.9%) had a diagnosis of SPC with a median interval of 11.1 months (range 078 months); 18 128 (38.7%) received cytotoxic chemotherapy (CC) and 1163 (2.5%) received ICIs for the treatment of the FPC in this period. SPCs were observed in 7/1163 (0.6%) patients who had received ICIs for their FPC versus 437/16 997 (2.6%) patients receiving CC and no ICIs for the FPC versus 1386/28 669 (4.8%) for patients receiving neither CC nor ICIs for the FPC. This reduction was observed at all ages and for all histotypes analyzed. Treatment with ICIs and/or CC for the FPC are associated with a reduced risk of SPC in multivariate analysis. Conclusion: Immunotherapy with ICIs alone and in combination with CC was found to be associated with a reduced incidence of SPC for all ages and cancer types.

引用

页数：9

共 31 条

[1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[2] Second cancers in survivors of childhood cancer [J].

Bhatia, S ;

Sklar, C .

NATURE REVIEWS CANCER, 2002, 2 (02) :124-+

[3] The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review [J].

Chai, Qing-Qing ;

Du, Jiang-Yang ;

Zhu, Jun ;

Wu, Bin .

FRONTIERS IN PHARMACOLOGY, 2019, 10

[4] Second primary cancers in non-Hodgkin lymphoma: Family history and survival [J].

Chattopadhyay, Subhayan ;

Zheng, Guoqiao ;

Sud, Amit ;

Sundquist, Kristina ;

Sundquist, Jan ;

Foersti, Asta ;

Houlston, Richard ;

Hemminki, Akseli ;

Hemminki, Kari .

INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (04) :970-976

[5] Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma [J].

Eggermont, Alexander M. M. ;

Blank, Christian U. ;

Mandala, Mario ;

Long, Georgina, V ;

Atkinson, Victoria ;

Dalle, Stephane ;

Haydon, Andrew ;

Lichinitser, Mikhail ;

Khattak, Adnan ;

Carlino, Matteo S. ;

Sandhu, Shahneen ;

Larkin, James ;

Puig, Susana ;

Ascierto, Paolo A. ;

Rutkowski, Piotr ;

Schadendorf, Dirk ;

Koornstra, Rutger ;

Hernandez-Aya, Leonel ;

Maio, Michele ;

van den Eertwegh, Alfonsus J. M. ;

Grob, Jean-Jacques ;

Gutzmer, Ralf ;

Jamal, Rahima ;

Lorigan, Paul ;

Ibrahim, Nageatte ;

Marreaud, Sandrine ;

van Akkooi, Alexander C. J. ;

Suciu, Stefan ;

Robert, Caroline .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) :1789-1801

[6] Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials [J].

Eichenauer, Dennis A. ;

Becker, Ingrid ;

Monsef, Ina ;

Chadwick, Nicholas ;

de Sanctis, Vitaliana ;

Federico, Massimo ;

Fortpied, Catherine ;

Gianni, Alessandro M. ;

Henry-Amar, Michel ;

Hoskin, Peter ;

Johnson, Peter ;

Luminari, Stefano ;

Bellei, Monica ;

Pulsoni, Alessandro ;

Sydes, Matthew R. ;

Valagussa, Pinuccia ;

Viviani, Simonetta ;

Engert, Andreas ;

Franklin, Jeremy .

HAEMATOLOGICA, 2017, 102 (10) :1748-1757

[7] The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study [J].

Feller, Anita ;

Matthes, Katarina L. ;

Bordoni, Andrea ;

Bouchardy, Christine ;

Bulliard, Jean-Luc ;

Herrmann, Christian ;

Konzelmann, Isabelle ;

Maspoli, Manuela ;

Mousavi, Mohsen ;

Rohrmann, Sabine ;

Staehelin, Katharina ;

Arndt, Volker .

BMC CANCER, 2020, 20 (01)

[8] Immunological and classical subtypes of oral premalignant lesions [J].

Foy, Jean-Philippe ;

Bertolus, Chloe ;

Ortiz-Cuaran, Sandra ;

Albaret, Marie-Alexandra ;

Williams, William N. ;

Lang, Wenhua ;

Destandau, Solene ;

De Souza, Genevieve ;

Sohier, Emilie ;

Kielbassa, Janice ;

Thomas, Emilie ;

Deneuve, Sophie ;

Goudot, Patrick ;

Puisieux, Alain ;

Viari, Alain ;

Mao, Li ;

Caux, Christophe ;

Lippman, S. M. ;

Saintigny, P. .

ONCOIMMUNOLOGY, 2018, 7 (12)

[9] The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy [J].

Havel, Jonathan J. ;

Chowell, Diego ;

Chan, Timothy A. .

NATURE REVIEWS CANCER, 2019, 19 (03) :133-150

[10] Risk Factors Associated With Secondary Sarcomas in Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study [J].

Henderson, Tara O. ;

Rajaraman, Preetha ;

Stovall, Marilyn ;

Constine, Louis S. ;

Olive, Aliza ;

Smith, Susan A. ;

Mertens, Ann ;

Meadows, Anna ;

Neglia, Joseph P. ;

Hammond, Sue ;

Whitton, John ;

Inskip, Peter D. ;

Robison, Leslie L. ;

Diller, Lisa .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (01) :224-230

← 1 2 3 4 →